Want to join the conversation?
$CCL 2Q15 Call – Arnold, CEO: A series of investments in product innovation, travel agent engagement, and marketing have delivered and the brand continues to outperform. The power of our diversified portfolio overcame the continental European brand challenges for macroeconomic and geopolitical uncertainties.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.